These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 17659757)

  • 1. Health-related quality of life and treatment burden in patients with proliferative lupus nephritis treated with cyclophosphamide or azathioprine/ methylprednisolone in a randomized controlled trial.
    Grootscholten C; Snoek FJ; Bijl M; van Houwelingen HC; Derksen RH; Berden JH;
    J Rheumatol; 2007 Aug; 34(8):1699-707. PubMed ID: 17659757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis.
    Grootscholten C; Bajema IM; Florquin S; Steenbergen EJ; Peutz-Kootstra CJ; Goldschmeding R; Bijl M; Hagen EC; Van Houwelingen HC; Derksen RH; Berden JH;
    Arthritis Rheum; 2007 Mar; 56(3):924-37. PubMed ID: 17328070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study.
    Khanna D; Yan X; Tashkin DP; Furst DE; Elashoff R; Roth MD; Silver R; Strange C; Bolster M; Seibold JR; Riley DJ; Hsu VM; Varga J; Schraufnagel DE; Theodore A; Simms R; Wise R; Wigley F; White B; Steen V; Read C; Mayes M; Parsley E; Mubarak K; Connolly MK; Golden J; Olman M; Fessler B; Rothfield N; Metersky M; Clements PJ;
    Arthritis Rheum; 2007 May; 56(5):1676-84. PubMed ID: 17469162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.
    Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; Garrido Ed Ede R; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
    Arthritis Rheum; 2002 Aug; 46(8):2121-31. PubMed ID: 12209517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2-year prospective study.
    Mok CC; Ho LY; Cheung MY; Yu KL; To CH
    Scand J Rheumatol; 2009; 38(2):121-7. PubMed ID: 18991189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-related quality of life in patients with systemic lupus erythematosus and proliferative lupus nephritis.
    Daleboudt GM; Berger SP; Broadbent E; Kaptein AA
    Psychol Health Med; 2011 Aug; 16(4):393-404. PubMed ID: 21749237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years.
    Moroni G; Doria A; Mosca M; Alberighi OD; Ferraccioli G; Todesco S; Manno C; Altieri P; Ferrara R; Greco S; Ponticelli C
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):925-32. PubMed ID: 17699309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis.
    Mok CC; Ying KY; Tang S; Leung CY; Lee KW; Ng WL; Wong RW; Lau CS
    Arthritis Rheum; 2004 Aug; 50(8):2559-68. PubMed ID: 15334470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis.
    Gunnarsson I; Sundelin B; Jónsdóttir T; Jacobson SH; Henriksson EW; van Vollenhoven RF
    Arthritis Rheum; 2007 Apr; 56(4):1263-72. PubMed ID: 17393458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis.
    Yee CS; Gordon C; Dostal C; Petera P; Dadoniene J; Griffiths B; Rozman B; Isenberg DA; Sturfelt G; Nived O; Turney JH; Venalis A; Adu D; Smolen JS; Emery P
    Ann Rheum Dis; 2004 May; 63(5):525-9. PubMed ID: 15082482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance.
    Hanly JG; McCurdy G; Fougere L; Douglas JA; Thompson K
    J Rheumatol; 2004 Nov; 31(11):2156-62. PubMed ID: 15517627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
    Hoyles RK; Ellis RW; Wellsbury J; Lees B; Newlands P; Goh NS; Roberts C; Desai S; Herrick AL; McHugh NJ; Foley NM; Pearson SB; Emery P; Veale DJ; Denton CP; Wells AU; Black CM; du Bois RM
    Arthritis Rheum; 2006 Dec; 54(12):3962-70. PubMed ID: 17133610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychometric properties of the EuroQol-5D and Short Form-6D in patients with systemic lupus erythematosus.
    Aggarwal R; Wilke CT; Pickard AS; Vats V; Mikolaitis R; Fogg L; Block JA; Jolly M
    J Rheumatol; 2009 Jun; 36(6):1209-16. PubMed ID: 19369452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial.
    Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; de Ramon Garrido E; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
    Arthritis Rheum; 2004 Dec; 50(12):3934-40. PubMed ID: 15593207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tacrolimus versus cyclophosphamide as treatment for diffuse proliferative or membranous lupus nephritis: a non-randomized prospective cohort study.
    Wang S; Li X; Qu L; Wang R; Chen Y; Li Q; He X; Zhang X; Wang H; Wu J; Xu Y; Chen J
    Lupus; 2012 Aug; 21(9):1025-35. PubMed ID: 22570338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens.
    Mok CC; Ho CT; Siu YP; Chan KW; Kwan TH; Lau CS; Wong RW; Au TC
    Am J Kidney Dis; 2001 Aug; 38(2):256-64. PubMed ID: 11479150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective study of anti-chromatin and anti-C1q autoantibodies in patients with proliferative lupus nephritis treated with cyclophosphamide pulses or azathioprine/methylprednisolone.
    Grootscholten C; Dieker JW; McGrath FD; Roos A; Derksen RH; van der Vlag J; Daha MR; Berden JH
    Ann Rheum Dis; 2007 May; 66(5):693-6. PubMed ID: 17135217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up of a randomised controlled trial of azathioprine/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis.
    Arends S; Grootscholten C; Derksen RH; Berger SP; de Sévaux RG; Voskuyl AE; Bijl M; Berden JH;
    Ann Rheum Dis; 2012 Jun; 71(6):966-73. PubMed ID: 22128082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life and economic burden of illness in very early arthritis. A population based study in southern Sweden.
    Söderlin MK; Kautiainen H; Skogh T; Leirisalo-Repo M
    J Rheumatol; 2004 Sep; 31(9):1717-22. PubMed ID: 15338489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors influencing change in health-related quality of life after liver transplantation.
    Estraviz B; Quintana JM; Valdivieso A; Bilbao A; Padierna A; de Urbina JO; Sarabia S
    Clin Transplant; 2007; 21(4):481-99. PubMed ID: 17645707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.